Market Overview

UPDATE: Barclays Downgrades Ariad Pharmaceuticals Following News of Iclusig Clinical Hold

Share:
Related ARIA
JMP Sees A 'Negative Market Tone' In Biotechnology
3 Stocks That Made A Big Impact At ASCO
ARIAD Pharma raises up to $200M in capital via synthetic royalty deal with PDL BioPharma; shares up 2% premarket (Seeking Alpha)

In a report published Thursday, Barclays analyst Ying Huang downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Overweight to Underweight, and lowered the price target from $25.00 to $4.00.

In the report, Barclays noted, “We are downgrading ARIA to UW from OW and reducing our price target to $4 from $25, on higher risk of Iclusig not receiving FDA approval as a front-line therapy for chronic myeloid leukemia (CML) and reduced peak sales in second-line treatment given safety concerns around cardiovascular, cerebrovascular, and peripheral vascular thrombosis. We see risk/reward skewed to the downside at current levels.”

Ariad Pharmaceuticals closed on Wednesday at $5.83.

Latest Ratings for ARIA

DateFirmActionFromTo
Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Barclays Capital Ying HuangAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ARIA)

Get Benzinga's Newsletters